PharVision Advisers’s BTCS Inc BTCS Stock Holding History

PharVision Advisers’s Portfolio BTCS Stock Details BTCS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-66,722	Closed	-$176K	–	173
2025 Q4	$176K	Buy	+66,722	New	+$241K	0.09%	593

Other funds holding BTCS

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Mirae Asset Global ETFs Holdings Causeway Bay, Hong Kong $73.7B AUM 53.56% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Vident Advisory Alpharetta, Georgia $11.7B AUM 37.32% 1-Year Est. Return

PharVision Advisers's BTCS Position: Q1 2026 in Review

PharVision Advisers sold out of BTCS Inc (BTCS) in Q1 2026, closing a stake of 66,722 shares — an estimated $176K sold.

PharVision Advisers first reported a position in BTCS in Q4 2025 and held it in 1 quarter. The position peaked at $176K in Q4 2025. 55 funds tracked by Wall St. Rank hold BTCS as of Q1 2026.

PharVision Advisers reported no remaining BTCS Inc position as of Q1 2026 after selling out during the quarter.
PharVision Advisers sold 66,722 BTCS Inc shares in Q1 2026, an estimated $176K.
PharVision Advisers first reported a position in BTCS Inc in Q4 2025 and held it in 1 quarter.
PharVision Advisers's BTCS Inc position peaked at $176K in Q4 2025.
55 funds tracked by Wall St. Rank held BTCS Inc as of Q1 2026.

Based on PharVision Advisers's 13F filing for Q1 2026, filed 22 Apr 2026.